UDP-Glucose dehydrogenase (UGDH) catalyzes the irreversible two-fold oxidation of UDP-glucose to produce UDP-glucuronic acid, which serves as an activated donor of glucuronic acid residues in a variety of biochemical pathways in nature. In mammals, it is a component of the glycosaminoglycans (heparin, hyaluronic acid, and chondroitin sulfate) that form the "matrix" or extracellular medium of connective tissue. In many pathogenic bacterial strains, UDP-glucuronic acid is a component of the organism's polysaccharide capsule. When capsule formation is disrupted, virulent strains of encapsulated bacteria become avirulent. Therefore, the development of inhibitors targeting UDP-glucuronic acid regulates its metabolic pathways and the activities of related enzymes, thereby intervening in specific diseases or pathological processes.
Fig.1 Specialized UDP-glucuronic acid inhibitor development service. (CD BioGlyco)
Technology: RNA interference (RNAi)
Journal: Biotechnology Letters
Results: UGDH catalyzes the production of UDP-glucuronide, and the authors used RNAi technology to knock down the expression of human UGDH. The siRNA of human UGDH was put into the pRNA-U6.1/Neo vector and chemically transfected into breast cancer cells. The results displayed that the expression of UGDH in the cells was effectively knocked down by RNAi at the protein level.
Fig.2 Construction of pU6-sihUGDH. (Huh, et al., 2005)
CD BioGlyco has professional technical talents and Glycosylation Inhibitor Development services, we have mature experience in the development of UDP-glucuronic acid inhibitors. Please feel free to contact us if you would like to acquire further information on inhibitor development.